Table 2.
HIV-1 Protein- or Peptide-Specific Antibodies Detected in CVL Using ELISA
| |
Laboratory A |
Laboratory B |
Laboratory C |
Laboratory D |
Laboratory E |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Clade B gp120 |
Clade C HIV lystate |
gp41 peptide 1 |
gp41 peptide 2 |
Clade C gp120 |
Clade B gp41 |
Clade C gp120 |
|||||||
| |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
IgG |
IgA |
| (% of total) | (% of total) | (reciprocal endpoint titer) | (mOD/min) | (reciprocal endpoint titer) | ||||||||||
| HIV-1 infected subjects | ||||||||||||||
| 1 | 1.35 | 0.28 | 4.1 | 0.30 | >1024 | – | 512 | – | >1267 | 265.4 | >320 | >16 | >320 | >16 |
| 2 | 3.67 | 0.26 | 21.1 | 0.93 | >1024 | – | 128 | – | >1267 | 23.8 | >320 | 8 | >320 | >16 |
| 3 | 1.29 | – | 1.2 | – | 512 | – | – | – | 114.7 | – | >320 | – | >320 | – |
| 4 | 0.37 | – | 1.8 | – | 128 | – | – | – | 10.2 | – | 320 | – | 80 | – |
| 5 | 0.47 | 0.06 | 2.1 | 1.31 | >1024 | – | 128 | – | 614.5 | 8.7 | >320 | – | >320 | 8 |
| 6 | 1.99 | 0.31 | 3.0 | – | >1024 | – | – | – | 484.7 | – | >320 | – | >320 | – |
| 7 | 1.37 | 0.17 | 9.3 | 0.15 | >1024 | – | – | – | 845.2 | 2.2 | >320 | 2 | >320 | 16 |
| 8 | 1.86 | 0.07 | 6.4 | – | >1024 | – | – | – | 381.1 | – | >320 | ≥16 | >320 | 4 |
| 9 | 0.57 | – | 0.7 | – | 64 | – | – | – | 25.9 | – | nd | – | nd | nd |
| 10 | 0.77 | 0.14 | 5.5 | 0.03 | 512 | – | – | – | 444.6 | 4.0 | ≥320 | – | >320 | 2 |
| 11 | 1.06 | 0.08 | 4.2 | – | 128 | – | – | – | 54.0 | 7.9 | ≥320 | – | 80 | – |
| 12 | 1.98 | – | 1.1 | – | >1024 | – | – | – | 73.5 | – | >320 | – | >320 | – |
| 13 | 1.13 | 0.14 | 23.4 | 0.29 | 256 | – | – | – | 46.9 | 1.3 | >320 | 2 | >320 | – |
| 14 | 1.12 | – | 5.2 | – | 256 | – | – | – | 537.8 | – | >320 | – | 80 | – |
| 15 | 0.69 | 0.22 | 10.9 | 2.08 | >1024 | – | 256 | – | >1267 | 32.3 | >320 | >16 | >320 | >16 |
| 16 | 0.48 | 0.07 | 0.3 | – | 16 | – | – | – | 12.9 | – | 20 | – | 20 | – |
| 17 | 0.42 | 0.28 | 17.7 | 1.32 | >1024 | – | – | – | >340 | 7.2 | >320 | – | >320 | – |
| 18 | 1.12 | – | 1.0 | – | 256 | – | – | – | 117.5 | – | >320 | – | 320 | – |
| 19 | 1.69 | – | 3.1 | – | 256 | – | 128 | – | >1267 | 3.9 | >320 | 2 | >320 | >16 |
| 20 | 2.71 | 0.16 | 3.3 | – | nd | – | nd | – | 71.8 | – | >320 | – | >320 | – |
| 21 | 0.33 | – | 8.5 | 0.03 | 256 | – | – | – | 22.2 | 3.3 | >320 | – | 80 | – |
| 22 | 0.94 | 0.16 | 9.8 | 0.37 | >1024 | – | 8 | – | 593.7 | 3.5 | >320 | – | >320 | >16 |
| 23 | 0.18 | 0.43 | 0.1 | – | 32 | – | – | – | 18.4 | 4.8 | 20 | – | 5 | 8 |
| 24 | 2.14 | 0.06 | 10.4 | 0.16 | >1024 | – | – | – | 255.3 | 7.1 | ≥320 | – | >320 | – |
| 25 | 0.82 | 0.40 | 1.6 | – | >1024 | – | 8 | – | 74.7 | – | >320 | 8 | >320 | – |
| 26 | 1.08 | 0.20 | 3.4 | – | >1024 | – | 8 | – | 225.6 | – | >320 | – | >320 | >16 |
| HEPSN subjects | ||||||||||||||
| 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 5 | – | 0.12 | – | – | – | – | – | – | – | – | – | – | – | – |
| 6 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 7 | – | – | – | – | – | – | – | – | – | – | nd | – | nd | nd |
| 8 | – | – | – | – | – | – | – | – | – | – | – | 2 | 5 | 4 |
| 9 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 10 | – | 0.85 | – | – | – | – | – | – | – | – | – | – | – | – |
| 11 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 12 | – | 0.26 | – | – | – | – | – | – | – | – | – | – | – | – |
| 13 | – | 0.32 | – | – | – | – | – | – | – | – | – | – | – | – |
| 14 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 15 | – | – | – | – | – | 16 | – | – | – | – | – | – | – | – |
| 16 | – | – | 0.07 | – | – | – | – | – | – | – | – | – | – | – |
| 17 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 18 | – | – | – | – | – | – | – | – | – | – | 5 | – | – | – |
| 19 | – | 0.53 | – | – | – | – | – | – | – | – | – | – | – | – |
| 20 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 21 | – | – | 0.08 | – | – | – | – | – | – | – | – | – | – | – |
| 22 | – | – | – | – | 8 | 8 | – | – | – | – | nd | – | – | – |
| 23 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 24 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 25 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 26 | – | – | – | – | 16 | 8 | 32 | – | – | – | 20 | 8 | 5 | 2 |
| 27 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 28 | – | – | – | – | – | – | – | – | 19.5 | – | – | – | – | – |
| 29 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 30 | – | – | – | – | – | – | 16 | – | – | – | 80 | 2 | 20 | – |
| 31 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 32 | – | – | – | – | nd | nd | nd | nd | – | – | – | – | – | – |
| 33 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 34 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 35 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 36 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 37 | – | – | – | – | – | – | – | – | – | – | – | 2 | – | – |
| 38 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 39 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 40 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 41 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Assays were performed as described in the Materials and Methods. Values shown are for specimens which were found to contain significant HIV-1-specific antibodies. Dashes denote the CVL that were negative. nd: not done.